Mattias Kalén
Uppsala University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Mattias Kalén.
Nature | 2007
Mats Hellström; Li-Kun Phng; Jennifer J. Hofmann; Elisabet Wallgard; Leigh Coultas; Per Lindblom; Jackelyn A. Alva; Ann-Katrin Nilsson; Linda Karlsson; Nicholas Gaiano; Keejung Yoon; Janet Rossant; M. Luisa Iruela-Arispe; Mattias Kalén; Holger Gerhardt; Christer Betsholtz
In sprouting angiogenesis, specialized endothelial tip cells lead the outgrowth of blood-vessel sprouts towards gradients of vascular endothelial growth factor (VEGF)-A. VEGF-A is also essential for the induction of endothelial tip cells, but it is not known how single tip cells are selected to lead each vessel sprout, and how tip-cell numbers are determined. Here we present evidence that delta-like 4 (Dll4)–Notch1 signalling regulates the formation of appropriate numbers of tip cells to control vessel sprouting and branching in the mouse retina. We show that inhibition of Notch signalling using γ-secretase inhibitors, genetic inactivation of one allele of the endothelial Notch ligand Dll4, or endothelial-specific genetic deletion of Notch1, all promote increased numbers of tip cells. Conversely, activation of Notch by a soluble jagged1 peptide leads to fewer tip cells and vessel branches. Dll4 and reporters of Notch signalling are distributed in a mosaic pattern among endothelial cells of actively sprouting retinal vessels. At this location, Notch1-deleted endothelial cells preferentially assume tip-cell characteristics. Together, our results suggest that Dll4–Notch1 signalling between the endothelial cells within the angiogenic sprout serves to restrict tip-cell formation in response to VEGF, thereby establishing the adequate ratio between tip and stalk cells required for correct sprouting and branching patterns. This model offers an explanation for the dose-dependency and haploinsufficiency of the Dll4 gene, and indicates that modulators of Dll4 or Notch signalling, such as γ-secretase inhibitors developed for Alzheimer’s disease, might find usage as pharmacological regulators of angiogenesis.
The EMBO Journal | 2002
Maria Enge; Mattias Bjarnegård; Holger Gerhardt; Erika Gustafsson; Mattias Kalén; Noomi Asker; Hans-Peter Hammes; Moshe Shani; Reinhardt Fässler; Christer Betsholtz
Loss of pericytes from the capillary wall is a hallmark of diabetic retinopathy, however, the pathogenic significance of this phenomenon is unclear. In previous mouse gene knockout models leading to pericyte deficiency, prenatal lethality has so far precluded analysis of postnatal consequences in the retina. We now report that endothelium‐restricted ablation of platelet‐derived growth factor‐B generates viable mice with extensive inter‐ and intra‐individual variation in the density of pericytes throughout the CNS. We found a strong inverse correlation between pericyte density and the formation of a range of retinal microvascular abnormalities strongly reminiscent of those seen in diabetic humans. Proliferative retinopathy invariably developed when pericyte density was <50% of normal. Our data suggest that a reduction of the pericyte density is sufficient to cause retinopathy in mice, implying that pericyte loss may also be a causal pathogenic event in human diabetic retinopathy.
American Journal of Pathology | 2003
Cecilia Bondjers; Mattias Kalén; Mats Hellström; Stefan J. Scheidl; Alexandra Abramsson; Oliver Renner; Per Lindahl; Hyeseon Cho; John H. Kehrl; Christer Betsholtz
All blood capillaries consist of endothelial tubes surrounded by mural cells referred to as pericytes. The origin, recruitment, and function of the pericytes is poorly understood, but the importance of these cells is underscored by the severe cardiovascular defects in mice genetically devoid of factors regulating pericyte recruitment to embryonic vessels, and by the association between pericyte loss and microangiopathy in diabetes mellitus. A general problem in the study of pericytes is the shortage of markers for these cells. To identify new markers for pericytes, we have taken advantage of the platelet-derived growth factor (PDGF)-B knockout mouse model, in which developing blood vessels in the central nervous system are almost completely devoid of pericytes. Using cDNA microarrays, we analyzed the gene expression in PDGF-B null embryos in comparison with corresponding wild-type embryos and searched for down-regulated genes. The most down-regulated gene present on our microarray was RGS5, a member of the RGS family of GTPase-activating proteins for G proteins. In situ hybridization identified RGS5 expression in brain pericytes, and in pericytes and vascular smooth muscle cells in certain other, but not all, locations. Absence of RGS5 expression in PDGF-B and PDGFR beta-null embryos correlated with pericyte loss in these mice. Residual RGS5 expression in rare pericytes suggested that RGS5 is a pericyte marker expressed independently of PDGF-B/R beta signaling. With RGS5 as a proof-of-principle, our data demonstrate the usefulness of microarray analysis of mouse models for abnormal pericyte development in the identification of new pericyte-specific markers.
Current Opinion in Lipidology | 1998
Per Lindahl; Mats Hellström; Mattias Kalén; Christer Betsholtz
The importance of perivascular-endothelial cell interactions during blood vessel development is discussed in the light of recent findings in platelet-derived growth factor-B, platelet-derived growth factor receptor-beta, angiopoietin-1 and tie-2 knockout mice, which all show deficient development of perivascular cells. The initial formation of networks of endothelial tubes (vasculogenesis) does not seem to depend on the perivascular cells but subsequent vessel remodeling relies on mesenchymal-endothelial short-range signaling. Based on findings in platelet-derived growth factor and platelet-derived growth factor receptor knockout mice, a general model for the role of platelet-derived growth factors in smooth muscle development is proposed.
American Journal of Pathology | 2002
Stefan J. Scheidl; Sven Nilsson; Mattias Kalén; Mats Hellström; Minoru Takemoto; Joakim Håkansson; Per Lindahl
Microarray hybridization has rapidly evolved as an important tool for genomic studies and studies of gene regulation at the transcriptome level. Expression profiles from homogenous samples such as yeast and mammalian cell cultures are currently extending our understanding of biology, whereas analyses of multicellular organisms are more difficult because of tissue complexity. The combination of laser microdissection, RNA amplification, and microarray hybridization has the potential to provide expression profiles from selected populations of cells in vivo. In this article, we present and evaluate an experimental procedure for global gene expression analysis of slender embryonic structures using laser microbeam microdissection and laser pressure catapulting. As a proof of principle, expression profiles from 1000 cells in the mouse embryonic (E9.5) dorsal aorta were generated and compared with profiles for captured mesenchymal cells located one cell diameter further away from the aortic lumen. A number of genes were overexpressed in the aorta, including 11 previously known markers for blood vessels. Among the blood vessel markers were endoglin, tie-2, PDGFB, and integrin-beta1, that are important regulators of blood vessel formation. This demonstrates that microarray analysis of laser microbeam micro-dissected cells is sufficiently sensitive for identifying genes with regulative functions.
Current topics in pathology. Ergebnisse der Pathologie; 93, pp 27-33 (1999) | 1999
Per Lindahl; Hans Boström; Linda Karlsson; Mats Hellström; Mattias Kalén; Christer Betsholtz
Platelet-derived growth factors (PGDFs) are 30-kDa dimeric proteins that exert their functions by binding to and activating PDGF receptors in the cell membrane [12, 22]. Two different PDGF monomers exist; the A chain and the B chain, and these may assemble into AA and BB homodimers as well as AB heterodimers. The two known PDGF-receptor proteins, the PDGF-α receptor (PDGF-Rα) and the β receptor (PDGF-Rβ) are both receptor tyrosine kinases and interact differentially with the PDGF molecules; PDGF-Rβ binds only the PDGF B chain with high affinity, whereas PDGF-Rα binds both chains with high affinity. Accordingly, the different PDGF dimers may bind to, dimerize and signal through different receptor pairs. Dimerization of the receptors is a prerequisite for signaling, since it allows for tyrosine phosphorylation of the intracellular part of the receptor molecules [11]. The resulting phosphotyrosine residues constitute binding sites for molecules carrying src-homology-2 (SH2) and other phosphotyrosine-binding domains. Their association with the PDGF receptor is a critical step in downstream signaling [5, 13].
The FASEB Journal | 2015
Maximilian Heiss; Mats Hellström; Mattias Kalén; Tobias May; Holger Weber; Markus Hecker; Hellmut G. Augustin; Thomas Korff
Given the need for robust and cost‐efficient in vitro models to study angiogenesis and reproducibly analyze potential pro‐ and antiangiogenic compounds in preclinical studies, we developed a 3‐dimensional in vitro angiogenesis assay that is based on collagen gel‐embedded, size‐defined spheroids generated from cultured human umbilical vein endothelial cells (HUVECs). Despite its wide distribution, limitations, sensitivity, robustness, and improvements, the capacity of this assay for functional screening purposes has not been elucidated thus far. By using time‐lapse video microscopy, we show that tip cells lead the formation of capillary‐like and partially lumenized sprouts originating from the spheroids. Angiogenic sprouting from spheroids generated from 5 different primary cultured human endothelial cell types was induced by physiologic concentrations of vascular endothelial cell growth factor 165. Based on this assay system, we determined the capacity of 880 approved drugs to interfere with or boost angiogenic sprouting, thereby assessing their putative angiogenesis‐related side effects or novel applications. However, although this assay allowed for a rapid and reproducible determination of functional IC50 values of individual compounds, the sprouting results were partially affected by the HUVEC passage number and donor variability. To overcome this limitation, immortalized HUVECs (iHUVECs) showing a more homogenous response in terms of proliferation and sprouting over multiple population doublings were used in the course of this study. Collectively, the spheroid‐based angiogenesis assay provides a sensitive and versatile tool to study the impact of pro‐ and antiangiogenic determinants on multiple steps of the angiogenic cascade. It is compatible with different endothelial cell types and allows use of iHUVECs to improve its overall robustness.—Heiss, M., Hellström, M., Kalén, M., May, T., Weber, H., Hecker, M., Augustin, H. G., Korff, T. Endothelial cell spheroids as a versatile tool to study angiogenesis in vitro. FASEB J. 29, 3076‐3084 (2015). www.fasebj.org
Chemistry & Biology | 2009
Mattias Kalén; Elisabet Wallgard; Noomi Asker; Aidas Nasevicius; Elisabet Athley; Erik Billgren; Jon D. Larson; Shannon A. Wadman; Elizabeth Norseng; Karl J. Clark; Liqun He; Linda Karlsson-lindahl; Ann Katrin Häger; Holger Weber; Hellmut G. Augustin; Tore Samuelsson; Chelsy K. Kemmet; Carly M. Utesch; Jeffrey J. Essner; Perry B. Hackett; Mats Hellström
We combined reverse and chemical genetics to identify targets and compounds modulating blood vessel development. Through transcript profiling in mice, we identified 150 potentially druggable microvessel-enriched gene products. Orthologs of 50 of these were knocked down in a reverse genetic screen in zebrafish, demonstrating that 16 were necessary for developmental angiogenesis. In parallel, 1280 pharmacologically active compounds were screened in a human cell-based assay, identifying 28 compounds selectively inhibiting endothelial sprouting. Several links were revealed between the results of the reverse and chemical genetic screens, including the serine/threonine (S/T) phosphatases ppp1ca, ppp1cc, and ppp4c and an inhibitor of this gene family; Endothall. Our results suggest that the combination of reverse and chemical genetic screens, in vertebrates, is an efficient strategy for the identification of drug targets and compounds that modulate complex biological systems, such as angiogenesis.
PLOS ONE | 2011
Mattias Kalén; Tommi Heikura; Henna Karvinen; Anja Nitzsche; Holger Weber; Norbert Esser; Seppo Ylä-Herttuala; Mats Hellström
The Notch signaling pathway is essential for normal development due to its role in control of cell differentiation, proliferation and survival. It is also critically involved in tumorigenesis and cancer progression. A key enzyme in the activation of Notch signaling is the gamma-secretase protein complex and therefore, gamma-secretase inhibitors (GSIs)—originally developed for Alzheimers disease—are now being evaluated in clinical trials for human malignancies. It is also clear that Notch plays an important role in angiogenesis driven by Vascular Endothelial Growth Factor A (VEGF-A)—a process instrumental for tumor growth and metastasis. The effect of GSIs on tumor vasculature has not been conclusively determined. Here we report that Compound X (CX), a GSI previously reported to potently inhibit Notch signaling in vitro and in vivo, promotes angiogenic sprouting in vitro and during developmental angiogenesis in mice. Furthermore, CX treatment suppresses tumor growth in a mouse model of renal carcinoma, leads to the formation of abnormal vessels and an increased tumor vascular density. Using a rabbit model of VEGF-A-driven angiogenesis in skeletal muscle, we demonstrate that CX treatment promotes abnormal blood vessel growth characterized by vessel occlusion, disrupted blood flow, and increased vascular leakage. Based on these findings, we propose a model for how GSIs and other Notch inhibitors disrupt tumor blood vessel perfusion, which might be useful for understanding this new class of anti-cancer agents.
Developmental Dynamics | 2012
Elisabet Wallgard; Anja Nitzsche; Jimmy Larsson; Xiaoyuan Guo; Lothar C. Dieterich; Anna Dimberg; Tommie Olofsson; Fredrik Pontén; Taija Mäkinen; Mattias Kalén; Mats Hellström
Background: Angiogenesis is implicated in many pathological conditions. The role of the proteins involved remains largely unknown, and few vascular‐specific drug targets have been discovered. Previously, in a screen for angiogenesis regulators, we identified Paladin (mouse: X99384, human: KIAA1274), a protein containing predicted S/T/Y phosphatase domains. Results: We present a mouse knockout allele for Paladin with a β‐galactosidase reporter, which in combination with Paladin antibodies demonstrate that Paladin is expressed in the vasculature. During mouse embryogenesis, Paladin is primarily expressed in capillary and venous endothelial cells. In adult mice Paladin is predominantly expressed in arterial pericytes and vascular smooth muscle cells. Paladin also displays vascular‐restricted expression in human brain, astrocytomas, and glioblastomas. Conclusions: Paladin, a novel putative phosphatase, displays a dynamic expression pattern in the vasculature. During embryonic stages it is broadly expressed in endothelial cells, while in the adult it is selectively expressed in arterial smooth muscle cells. Developmental Dynamics 241:770–786, 2012.